(Q34675396)

3 August 2017

1 reference

title

Hepatorenal syndrome. Definition, pathophysiology, and intervention (English)

1 reference

3 August 2017

1 reference

Andrew E Briglia

1

1 reference

3 August 2017

Frank A Anania

series ordinal

2

1 reference

3 August 2017

publication date

1 April 2002

1 reference

3 August 2017

published in

Critical Care Clinics

1 reference

3 August 2017

volume

18

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

345-373

1 reference

Use of extracorporeal ascites dialysis in combined hepatic and renal failure

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Dialysis disequilibrium syndrome: current concepts on pathogenesis and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Effects of bicarbonate- and lactate-buffered replacement fluids on cardiovascular outcome in CVVH patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Practical recommendations for the treatment of ascites and its complications

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Continuous arteriovenous haemodiafiltration in the critically ill: Influence on major nutrient balances

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Effect of continuous venovenous hemofiltration with dialysis on hormone and catecholamine clearance in critically ill patients with acute renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Response to Dopamine Hydrochloride in the Hepatorenal Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Hepatorenal syndrome and ascites--questions and answers

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Effects of serial resin hemoperfusion in fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Acute renal failure in the intensive care unit. Therapy overview, patient risk stratification, complications of renal replacement, and special circumstances

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Spontaneous dialytic ultrafiltration with intraperitoneal reinfusion of the concentrate versus large paracentesis in cirrhotic patients with intractable ascites: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Renal Failure Associated with Demeclocycline in Cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Hepatocirculatory failure: diverse pathogeneses deserve diverse therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Systemic vasoconstrictor and renal vasodilator effects of PLV-2 (octapressin) in man

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Rebound surges of intracranial pressure as a consequence of forced ultrafiltration used to control intracranial pressure in patients with severe hepatorenal failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Changes in intracranial pressure during haemofiltration in oliguric patients with grade IV hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Continuous arteriovenous haemofiltration in patients with hepatic encephalopathy and renal failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Haemofiltration in patients with fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Amino acid losses during haemofiltration

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Amino acid clearances and daily losses in patients with acute renal failure treated by continuous arteriovenous hemodialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Hepatorenal syndrome without avid sodium retention

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Reversal of hepatorenal syndrome with the combination of norepinephrine and dopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Renal failure in liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Combined Ascitic-Fluid and Furosemide Infusion in the Management of Ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Continuous arterio-venous ultrafiltration in cirrhotic patients with ascites or renal failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Continuous arterio-venous ultrafiltration in the management of the renal complications of liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

The hepatorenal syndrome--newer perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Treatment of hepatic coma and hepatorenal syndrome. Mechanism of action of L-dopa and aramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Glucose dynamics during continuous hemodiafiltration and total parenteral nutrition

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Amino acid loss and plasma concentration during continuous hemodiafiltration

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Hepatorenal syndrome and ascites--an introduction

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Effects of OKY 046, a thromboxane-synthase inhibitor, on renal function in nonazotemic cirrhotic patients with ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Pathophysiology of renal dysfunction in cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Continuous arterio-venous haemodialysis during emergency hepatic retransplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome--experience in 300 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Acute changes in renal excretion of water and solute in patients with Laennec's cirrhosis, induced by the administration of the pressor amine, metaraminol

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Which amino-acids do serum and hemofiltrate of critically ill patients with acute renal failure contain?

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Effect of the dialysis membrane in the treatment of patients with acute renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Extracorporeal diaglysis of ascites. A new technique

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Improvement in renal function in hepatorenal syndrome with N-acetylcysteine.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Use of sorbent columns and haemofiltration in fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Amino acid losses during hemodialysis: effects of high-solute flux and parenteral nutrition in acute renal failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Amino acid and albumin losses during hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Continuous haemoperfusion for fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Haemodialysis-membrane biocompatibility and mortality of patients with dialysis-dependent acute renal failure: a prospective randomised multicentre trial. International Multicentre Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Continuous arteriovenous hemofiltration. A report of six months' experience

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Risk Factors and Outcome of 107 Patients with Decompensated Liver Disease and Acute Renal Failure (Including 26 Patients with Hepatorenal Syndrome): The Role of Hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Amino acid losses and nitrogen balance during slow diurnal hemodialysis in critically ill patients with renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Thromboxane-receptor blockade increases water diuresis in cirrhotic patients with ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

New clues to the pathophysiology of hepatorenal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Continuous Arteriovenous Hemofiltration in the Critically Ill Patient

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Plasmapheresis with plasma exchange in hepatic coma. Methods and results in five patients with acute fulminant hepatic necrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Liver disease, aminoglycoside antibiotics and renal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Continuous renal replacement therapies: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Peritoneal dialysis in end-stage renal disease patients with preexisting chronic liver disease and ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Continuous removal of middle molecules by hemofiltration in patients with acute liver failure

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Effects of lactate-buffered and lactate-free dialysate in CAVHD patients with and without liver dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Uptake of glucose during continuous arteriovenous hemofiltration

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Removal of endotoxin and cytokines by adsorbents and the effect of plasma protein binding

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

1 reference

7 January 2021

Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Postdilution hemofiltration in the management of acute hepatic failure: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Ascites and hepatorenal syndrome: pathophysiology and management

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Control of cerebral oedema by total hepatectomy and extracorporeal liver support in fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Development of a hybrid bioartificial liver

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Continuous arteriovenous haemodialysis during emergency hepatic retransplantation: two case reports

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Biocompatible membranes in acute renal failure: prospective case-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Inhibition of rat brain Na+,K+-ATPase activity by serum from patients with fulminant hepatic failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

RENAL FAILURE IN PATIENTS WITH CIRRHOSIS OF THE LIVER. I. CLINICAL AND PATHOLOGIC CHARACTERISTICS

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

RENAL FAILURE IN PATIENTS WITH CIRRHOSIS OF THE LIVER. II. FACTORS INFLUENCING MAXIMAL URINARY FLOW RATE

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Urinary sodium and chloride during renal salt retention

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Renal function in obstructive jaundice in man: cholangiocarcinoma model

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Amelioration of hepatorenal syndrome with selective endothelin-A antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Treatment of acute liver failure with hemodetoxification techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Natriuretic effect of an adenosine-1 receptor antagonist in cirrhotic patients with ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Concomitant renal and hepatic failure treated by polyacrylonitrile membrane hemodialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Drug dosing in acute renal failure: the role of renal replacement therapy in altering drug pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Extracorporeal liver assist in the treatment of fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Dopamine in the Hepatorenal Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Amino acid losses during hemodialysis with infusion of amino acids and glucose.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Therapy for hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Digoxin-like immunoreactive substances in severe acute liver disease due to viral hepatitis and paracetamol overdose

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Improvement of renal failure with repeated head-out water immersions in patients with hepatorenal syndrome associated with alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Development of reliable artificial liver support (ALS)--plasma exchange in combination with hemodiafiltration using high-performance membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

Gentamicin and gram-negative bacteremia. A synergism for the development of experimental nephrotoxic acute renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900003-3

7 January 2021

10.1016/S0749-0704(01)00003-3

Identifiers

DOI

1 reference

3 August 2017

1 reference